Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Manhattan Pharmaceuticals, Inc. (now TG Therapeutics, Inc.) on April 16, 2012. The filing details the results of five proposals submitted to security holders, including the election of directors, corporate restructuring measures, and the appointment of auditors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders representing 53.43% of the 839,091,977 shares entitled to vote participated in the meeting. All five management proposals were approved:
- Proposal 1 (Election of Directors): Five directors were elected to serve until the 2013 annual meeting: Michael S. Weiss, Neil Herskowitz, Laurence N. Charney, William J. Kennedy, and Mark Schoenebaum, MD. Voting was overwhelmingly in favor, with votes withheld ranging from approximately 3.6 million to 5.6 million per director.
- Proposal 2 (Reverse Stock Splits): Shareholders approved an amendment to the Certificate of Incorporation to effect up to two reverse stock splits. Votes were 439,183,524 for, 8,620,124 against, and 576,575 abstentions.
- Proposal 3 (Name Change): Shareholders authorized the Board to change the company name from "Manhattan Pharmaceuticals, Inc." to "TG Therapeutics, Inc." Votes were 445,692,417 for, 2,141,187 against, and 546,619 abstentions.
- Proposal 4 (Incentive Plan): The 2012 Incentive Plan was adopted. Votes were 422,826,292 for, 12,884,496 against, and 10,067,395 abstentions.
- Proposal 5 (Auditor Appointment): J.H. Cohn LLP was appointed as the independent registered public accounting firm for the 2012 fiscal year. Votes were 445,861,077 for, 2,287,348 against, and 231,798 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves strictly as a record of the shareholder vote.
Important Facts for Investors to Verify
- Confirmation that the name change to "TG Therapeutics, Inc." has been legally finalized and reflected in trading symbols.
- Details regarding the timing and ratio of the approved reverse stock splits, as the Board retains discretion to determine the specifics.
- The terms and share limits of the newly adopted 2012 Incentive Plan.
- Subsequent financial filings (10-K or 10-Q) to assess the company's liquidity and operational status, as this 8-K contains no financial data.